The method and active ingredient for the replacement of morphine-containing drugs were discovered by Dr. Zoltán Oláh and his colleagues in 1998 and taken from the laboratory to the patients (Bench-to-Bedside, B2B) in the USA (NIH, Bethesda MD). This procedure has since entered into the literature under the name of "molecular neurosurgery" (Pecze, et al. 2017). The mechanism of molecular neurosurgery, that is in Phase II, is a selective solution for inflammatory pain. It is especially important to emphasize that there are no toxic or hallucinogenic side effects of this pain killer mechanism (Olah, et al. 2001; Pecze, et al. 2017)
From Phase II, with the start of this treatment in Hungary, the market opening of this selective, morphine-free analgesics targeted at inflammatory chronic pain could continue, if the decision-makers would see the enormous importance of this fundamentally new procedure. This is the "secret" of making cost-effective use of the U.S. state-capitalist R&D system.
A short film about a veterinary clinical trial: